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Background: The OLIVUS trial, using volumetric IVUS, reported a positive role in
achieving a potentially lower rate of coronary atheroma progression through the
administration of Olmesartan, an angiotension-II receptor blocker (ARB), for stable
angina pectoris (SAP) patients requiring percutaneous coronary intervention (PCI).
However, the benefits between ARB administration on long-term clinical outcomes and
serial atheroma changes by IVUS remain unclear. Thus, we examined the 5-year clinical
outcomes from OLIVUS according to treatment strategy with Olmesartan.
Methods: In the OLIVUS trial, serial volumetric IVUS examinations (baseline and 14
months) were performed in 247 patients with SAP. When patients underwent PCI for
culprit lesions, IVUS was performed in their non-culprit vessels. Patients were randomly
assigned to receive 20-40mg of Olmesartan or control, and treated with a combination of
-blockers, calcium channel blockers, diuretics, glycemic control agents and/or statins per
physician’s guidance. Five-year clinical outcomes and annual progression rate of
atherosclerosis, assessed by IVUS (mean lengths 43mm), were compared with major
adverse cardio- and cerebrovascular events (MACCE).
Results: Cumulative event-free survival was significantly higher in the Olmesartan group
than in the control group (p0.04; log-rank test). By adjusting for validated prognosti-
cators, Olmesartan administration was identified as a good predictor of MACCE (HR
0.73, 95%CI 0.49-0.88; p0.04). On the other hand, patients with adverse events (n38)
had larger annual atheroma progression than the rest of the population (22.417.9% vs.
2.414.1%, P0.001).
Control Olmesartan p-value
n 121 126
14-months follow-up (%)
Plaque Volume Change 5.4 15.5 0.6 12.9 0.016
Percent Change in Plaque Volume 3.6 9.5 0.7 8.4 0.038
In-stent Restenosis 10.7 7.9 0.42
5-Years Follow-up (%)
Composite MACCE 20.4 10.4 0.034
Cardio-, cerebral Death 2.2 1.2 0.75
Non-fatal Stroke 1.7 0.3 0.08
Myocardial Infarction 1.6 1.6 0.89
Unstable/Progressive Angina 12.4 6.5 0.10
(Culprit Related/De novo Lesions) (5.4/6.8) (3.4/3.1)
Deteriation of Heart/Renal Failure 2.5 0.8 0.30
Conclusions: Olmesartan therapy appears to confer improved long-term clinical out-
comes. Atheroma volume changes, assessed by IVUS, seem to be a reliable surrogate for
future MACCE in this study cohort.
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Background: Prior studies have shown that statin may stabilize atheromatous plaques by
increasing fibrous-cap thickness. The aim of this study was to examine statin pretreatment
on plaque vulnerability assessed by intravascular ultrasound (IVUS) and optical coher-
ence tomography (OCT) in patients with stable angina pectoris (SAP).
Methods: Culprit plaques in 110 patients with SAP were interrogated by both IVUS and
OCT before percutaneous coronary intervention (PCI). Volumetric analyses were per-
formed for external elastic membrane (EEM), lumen, and plaque plus media at 1-mm
intervals for 11 IVUS images per patient. The thinnest part of the fibrous cap was
measured by OCT.
Results: In patients with statin pretreatment, low density lipoprotein-cholesterol (LDL-C)
level (n  73) was lower than those without statin pretreatment (n  37) (80mg/dl vs.
113mg/dl, P0.01). Patients with statin pretreatment had smaller EEM volume, plaque plus
media volume, and plaque burden than those without (107 mm3 vs. 129 mm3, P0.05, 65
mm3 vs. 91 mm3, P0.01, and 62% vs. 71%, p 0.01, respectively). By OCT, Patients with
statin pretreatment had a lower incidence of lipid rich plaque than those without (43% vs. 68%,
P0.02). Statin pretreatment was associated with thicker fibrous cap thickness (115m vs
90m, P0.03) and fewer incidence of thin-cap fibroatheroma (TCFA) (6% vs. 22%, p 
0.02). Multivariate logistic regression analysis identified statin pretreatment as a negative
determinant of lipid rich plaque and TCFA independent of age, gender, LDL-C, and
high-sensitivity C-reactive protein (odds ratio 0.36; 95% CI 0.16–0.83, p  0.02 and odds
ratio 0.21; 95% CI 0.06–0.75, p  0.02, respectively).
Conclusions: In patients with SAP, lack of statin pretreatment was associated with larger
plaque volume and more vulnerable plaque morphology independent of LDL-C levels.
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Background: Angiographic ectasias and aneurysms in stented segments have been
associated with a risk of late stent thrombosis. Using optical coherence tomography
(OCT) at follow-up, some stented segments show coronary evaginations reminiscent of
ectasias. The occurrence, predictors and mechanisms of evaginations following drug-
eluting stent (DES) implantation are unknown.
Methods: Evaginations were defined as outward bulges in the luminal contour between
struts. They were considered major evaginations (ME) when present in 3 consecutive
frames, with a depth 10% of the stent diameter. A total of 228 patients who had
sirolimus (SES)-, paclitaxel-, biolimus-, everolimus (EES)-, or zotarolimus (ZES)-eluting
stents implanted in 254 lesions, were analysed after 1, 2 or 5 years; and serial assessment
using OCT and intravascular ultrasound (IVUS) was performed post intervention and
after 1 year in 42 patients.
Results: ME occurred frequently at all time points in SES (26%) and were rarely seen
in EES (3%) and ZES (2%, p0.003). SES implantation was the strongest independent
predictor of ME (adjusted OR [95% CI]: 10.3 [1.3-85.5, p0.01). Malapposed and
uncovered struts were more common in lesions with vs. without ME (77% vs. 25%,
p0.001, and 95% vs. 20%, p0.001, respectively). Post-intervention intra-stent dissec-
tion and protrusion of the vessel wall into the lumen were associated with an increased risk
of evagination at follow-up (OR [95% CI]: 2.9 [1.8-4.9], p0.001 and 3.3 [1.6-6.9],
p0.001, respectively). In paired IVUS analyses, ME showed a larger increase in the
external elastic membrane area (20% area change) compared with lesions without ME
(5% area change, p0.001).
Conclusions: OCT-detected coronary evaginations are a morphological footprint of
early-generation SES and are nearly absent in newer-generation DES. Evaginations
appear to be related to vessel injury at baseline, and are mainly caused by positive vessel
remodeling.
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Background: C-reactive protein (CRP) levels sometimes elevate during admission
without any inflammatory symptom after onset of acute coronary syndrome, although its
clinical significance remains unknown. In this study, we investigated the relation between
peak high sensitivity CRP (hs-CRP) levels and culprit lesion morphology by optical
coherence tomography study (OCT) in the acute phase of non-ST-segment elevation acute
coronary syndrome (NSTEACS).
Methods: Culprit plaques in 100 patients with NSTEACS, who received elective
percutaneous coronary intervention (PCI), were interrogated by OCT before PCI. The
blood samples were obtained from all patients 0, 3, and 6 hours after admission and every
day until coronary angiography. Patients were divided into high peak hs-CRP group (peak
hs-CRP 50 mg/l) and low peak hs-CRP group (peak hs-CRP50 mg/l) on the basis of
highest hs-CRP levels before coronary angiography.
Results: Patients in high peak hs-CRP group (N23) had higher Troponin I levels than
those in the low peak hs-CRP group (N77) (0.17ng/ml vs. 0.07ng/ml, P0.02). We
observed significantly more plaque rupture (78% vs. 47%, P0.01), thrombus (96% vs.
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